Literature DB >> 10332965

Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: a novel mechanism of activation of synoviocytes.

M Harigai1, M Hara, S Nakazawa, C Fukasawa, S Ohta, T Sugiura, K Inoue, S Kashiwazaki.   

Abstract

OBJECTIVE: To determine the immunopathological significance of CD40/CD40 ligand (CD40L) interaction in rheumatoid arthritis (RA).
METHODS: The expression of CD40 ligand (CD40L) in synovial tissues (ST) from patients with RA was examined by immunohistochemistry. Tumor necrosis factor-alpha (TNF-alpha) was measured by ELISA. Expression of CD40 on ST cells was quantified by anti-CD40 monoclonal antibodies and 125I labelled anti-mouse IgG.
RESULTS: Immunohistochemistry showed CD40L+ T cells in RA ST. Ligation of CD40 on RA ST cells significantly increased the production of TNF-alpha in a dose dependent fashion. Adherent, but not non-adherent, fraction of ST cells responded to ligation of CD40 to produce TNF-alpha. Interferon-gamma (IFN-gamma), interleukin 4 (IL-4), or IL-13 acted synergistically with CD40 ligation to enhance TNF-alpha production by ST cells. IL-10 exerted inhibitory effects on both CD40 ligation induced and CD40 ligation plus IFN-gamma induced TNF-alpha production by ST cells.
CONCLUSION: These data indicate activated T cells participate in synovial inflammation of RA via CD40L to stimulate the production of TNF-alpha by ST cells. The effect of CD40 ligation is modulated by the presence of several cytokines, e.g., IFN-gamma, IL-4, IL-10, and IL-13.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10332965

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

Review 1.  Targeting CD40L: a promising therapeutic approach.

Authors:  Dimitris Daoussis; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

2.  Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis.

Authors:  B Berner; G Wolf; K M Hummel; G A Müller; M A Reuss-Borst
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

Review 3.  B-cell involvement in the pathogenesis of RA-is there a contribution of the sympathetic nervous system?

Authors:  Georg Pongratz; Rainer H Straub
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 4.  CD40 and autoimmunity: the dark side of a great activator.

Authors:  Anna L Peters; Laura L Stunz; Gail A Bishop
Journal:  Semin Immunol       Date:  2009-10       Impact factor: 11.130

Review 5.  Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy.

Authors:  Andrew G Gianoukakis; Terry J Smith
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-10       Impact factor: 3.243

Review 6.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

7.  A CD40 variant is associated with systemic bone loss among patients with rheumatoid arthritis.

Authors:  Rim Sghiri; Hana Benhassine; Khadija Baccouche; Meriem Ghozzi; Sarra Jriri; Zahid Shakoor; Adel Almogren; Foued Slama; Nadia Idriss; Zeineb Benlamine; Elyes Bouajina; Ramzi Zemni
Journal:  Clin Rheumatol       Date:  2022-02-02       Impact factor: 2.980

Review 8.  CD154: the atherosclerotic risk factor in rheumatoid arthritis?

Authors:  Ghada S Hassan; Daniel Yacoub; Nada Alaaeddine; Amal Nadiri; Yahye Merhi; Walid Mourad
Journal:  Arthritis Res Ther       Date:  2013-02-22       Impact factor: 5.156

Review 9.  CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Nada Alaaeddine; Ghada S Hassan; Daniel Yacoub; Walid Mourad
Journal:  Clin Dev Immunol       Date:  2011-10-24

10.  Attenuation of murine antigen-induced arthritis by treatment with a decoy oligodeoxynucleotide inhibiting signal transducer and activator of transcription-1 (STAT-1).

Authors:  Marion Hückel; Uta Schurigt; Andreas H Wagner; Renate Stöckigt; Peter K Petrow; Klaus Thoss; Mieczyslaw Gajda; Steffen Henzgen; Markus Hecker; Rolf Bräuer
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.